Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients

Inclusion Criteria: * Female patients with breast cancer. * Age ≥18 \& ≤ 65 years. * Newly diagnosed, chemotherapy-naïve patients. * Baseline echocardiogram showing left ventricular ejection fraction (LVEF) ≥55%. Exclusion Criteria: * Presence of hypersensitivity to telmisartan. * History of cardiovascular disease (e.g., congestive heart failure, ischemic heart disease, arrhythmia). * Patients with any chronic liver or renal dysfunction; inflammatory diseases; autoimmune disease; acute cardiovascular events, eating disorders (anorexia, bulimia) or gastrointestinal disorders. * Baseline blood pressure ≥ 160/100 mmHg * Current or prior use of ARBs/ACE inhibitors * Current participation in another clinical trial within the past 30 days. * Pregnant or breastfeeding women.